Literature DB >> 6712393

Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole.

R Feld, A Rachlis, P G Tuffnell, I Duncan, L Moran, P Pinfold, G DeBoer.   

Abstract

A combination of tobramycin sulfate and cefamandole nafate was used as initial empiric therapy for the treatment of 71 evaluable febrile (temperature greater than 38.5 degrees C) episodes in 64 (neutrophils, less than 1,000/microL) adult patients with cancer and granulocytopenia. Carbenicillin sodium or ticarcillin disodium was substituted for cefamandole in patients with Pseudomonas infections and in patients in whom the initial regimen was unsuccessful. Twenty-nine episodes were randomized to receive tobramycin by continuous infusion, while 42 were randomized to receive tobramycin by interrupted infusion. Twenty-seven (79%) of the 34 documented infections responded to the initial empiric antibiotic combination, ten (83%) of 12 being given continuous infusion and 17 (77%) of 22 being given interrupted infusion of tobramycin. Nephrotoxic reaction occurred in 7% of patients treated with continuous infusion and 15% treated with interrupted infusion, mostly patients older than 60 years. Tobramycin, by either continuous or interrupted infusion, plus cefamandole is safe and efficacious empiric therapy for infections in patients with cancer and granulocytopenia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6712393

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  8 in total

Review 1.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Once-daily dosing of aminoglycosides.

Authors:  J Blaser; C König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

Review 3.  Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters.

Authors:  Sofia K Kasiakou; Kenneth R Lawrence; Nicolaos Choulis; Matthew E Falagas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients.

Authors:  B de Pauw; K Williams; J de Neeff; T Bothof; T de Witte; R Holdrinet; C Haanen
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

5.  Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever.

Authors:  G Bodey; A Reuben; L Elting; H Kantarjian; M Keating; F Hagemeister; C Koller; W Velasquez; N Papadopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

Review 6.  What is the evidence for once-daily aminoglycoside therapy?

Authors:  M L Barclay; E J Begg; K G Hickling
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

7.  Single or multiple daily doses of aminoglycosides: a meta-analysis.

Authors:  M Barza; J P Ioannidis; J C Cappelleri; J Lau
Journal:  BMJ       Date:  1996-02-10

Review 8.  Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections.

Authors:  Jennifer Shiu; Erica Wang; Aaron M Tejani; Michael Wasdell
Journal:  Cochrane Database Syst Rev       Date:  2013-03-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.